Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis

References

• Poon TC, Wang N, Lai PB, Rattray M, Johnson PJ, Sung JJ. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology 2006;131:1262–70.
   PubMedGoogle Scholar
• Kumada T, Toyoda H, Tada T, Sone Y, Fujimori M, Ogawa S, et al. Evolution of hypointence hepatocellular nodules observed only in the hepatobiliary phase using Gd-EOB-DTPA enhanced magnetic resonance imaging. Am J Roent 2011;197:58–63.
   PubMed Web of Science ®Google Scholar
• Kojiro M. Pathology of early hepatocellular carcinoma – Progression from early to advanced –. Hepat Gastroent 1998;45:1203–5.
   PubMedGoogle Scholar
• Sugihara S, Nakashima O, Kojiro M, Majima Y, Tanaka M, Tanikawa K, et al. The morphologic transition in hepatocellular carcinoma – a comparison of the individual histological features disclosed by ultrasound-guided fine-needle biopsy with at autopsy. Cancer 1992;70:1488–92.
   PubMedGoogle Scholar
• Ikeda K, Saitho S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47–53.
   PubMed Web of Science ®Google Scholar
• Vasiliev JM, Moizhess TG. Tumorigenicity of sarcoma cells is enhanced by the local environment of implanted foreign body. Int J Cancer 1982;30:525–9.
   PubMed Web of Science ®Google Scholar
• Hamada J, Takeichi N, Okuda F, Ren J, Li X, Hosokawa M, et al. Progression of weakly malignant clone cells derived from rat mammary carcinoma by host cells reactive to plastic plates. Jpn J Cancer Res 1992;83:483–90.
   PubMedGoogle Scholar
• Rincon M, James T, Bunn J. The role of post surgical inflammation in tumor progression in breast cancer [abstract number 392]. AACR Annual Meeting, 2012.
   Google Scholar
• Deng J, Fujimoto J, Ye XF, Men TY, Van Peit CS, Chen YL, et al. Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila) 2010;3:424–37.
   PubMed Web of Science ®Google Scholar
• Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009;462:104–7.
   PubMed Web of Science ®Google Scholar
• Muto M. Inflammation-induced tumor progression and its prevention. Exp Med 2011;29:139–44; in Japanese.
   Google Scholar
• Okuda Y, Sawai H, Tanaka M, Manabe T. The role of inflammatory cytokine, IL-1 in the development of invasive pancreatic cancer. Jap J Gastroent Surg 2004;37:1331; in Japanese.
   Google Scholar
• Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73.
   PubMed Web of Science ®Google Scholar
• Knodell RG, Ishak KG, Black WC, Chen TS, Craig CR, Kaplowits N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431–5.
   PubMed Web of Science ®Google Scholar
• Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumors of the digestive system. Lyon: IARC press; 2010. pp 211–12.
   Google Scholar
• Karin M, Cao Y, Greten FR, Li Z-W. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301–10.
   PubMed Web of Science ®Google Scholar
• Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680–3.
   PubMed Web of Science ®Google Scholar
• Wang W, Abbruzzese JL, Evans DP, Chiao PJ. Overexpression of urokinase-type plasmionogen activator in pancreatic adenocarcinoma is upregulated by constitutively activated RelA. Oncogene 1999;18:4554–63.
   PubMed Web of Science ®Google Scholar
• Ikebe T, Takeuchi H, Jimi E, Beppu M, Shinohara M. Involvement of proteasome in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma. Int. J. Cancer 1998;77:578–87.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T. Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer Res 2000;60:3978–84.
   Google Scholar
• Kim IY, Stactman TC. Inhibition of NF-κB DNA binding and nitric oxide induction in human T cell and lung adenocarcinoma cells. Proc Natl Acad Sci USA 1997;94:12904–7.
   PubMed Web of Science ®Google Scholar
• Hinz M, Krappmann D, Eichten A, Heder A, Scheidereic C, Strauss M. Nf-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to S-phase transition. Mol Cell Biol 1999;19:2690–8.
   PubMed Web of Science ®Google Scholar
• Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, et al. Nuclear factor-κB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001;7:4136–42.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Karin M. NF-κB: a pivotal transcription factor in chronic inflammatory disease. N Engl J Med 1997;336:1066–71.
   PubMed Web of Science ®Google Scholar
• Carbone C, Melsi D. NF-Kappa B as a target for pancreatic cancer therapy. Expert Opin Ther Targets 2012;16:51–60.
   Google Scholar
• Pan H, Fu K, Huang W. Molecular mechanism of liver cancer. Anti-Canc. Agent in Med Chem 2011;11:439–99.
   Google Scholar
• Okuda K. Space occupying lesions. In Okuda K, editor. Hepatobiliary diseases. Philadelphia: Blakwell Science; 2000. pp 395.
   Google Scholar
• Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999;86:589–95.
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol 2006;41:1087–94.
   PubMed Web of Science ®Google Scholar
• Miyakawa K, Tarao K, Ohshige K, Morinaga S, Ohkawa S, Okamoto N, et al. High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis. Scand J Gastroenterol 2009;44:1340–8.
   PubMed Web of Science ®Google Scholar
• Tarao K, Ohkawa S, Shimizu A, Harada M, Nakamura Y, Okamoto N, et al. DNA synthesis activities of hepatocytes from noncancerous cirrhotic tissue and of hepatocellular carcinoma (HCC) cells from cancerous tissue can predict the survival of hepatectomized patients with HCC. Cancer 1993;71:3859–63.
   PubMedGoogle Scholar
• Suzuki F, Ikeda K, Toyota J, Karino Y, Ohmura T, Chayama K, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or patients ineligible/intoleranto to peginterferon/ribavirin [Abstract 2344]. The International Liver Congress 2012: 47th Annual Meeting of the European Association for the Study of the Liver Barcelona, Spain, April 18–22 2012.
   Google Scholar
• Shiffman ML, Hoffmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164–72.
   PubMed Web of Science ®Google Scholar
• Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, et al. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection. Intervilorogy 2004;47:355–61.
   PubMedGoogle Scholar
• Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, et al. Interferon-induced prolonged biochemical responce reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 2007;79:1485–90.
   PubMedGoogle Scholar
• Nomura H, Kashiwagi Y, Hirano R, Tanimoto H, Tsutsumi N, Higashi M, et al. Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetorotein: a pilot study. Hepatology Res 2007;37:490–7.
   PubMedGoogle Scholar
• Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011;140:840–9.
   PubMed Web of Science ®Google Scholar
• Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993;19:459–64.
   PubMed Web of Science ®Google Scholar
• Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, et al. A large-scale, multicenter, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007;56:1747–53.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Ohta Y, Takino T, Fujisawa K, Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis-double blind trial. Asian Med J 1983;26:423–8.
   Google Scholar
• Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494–500.
   PubMed Web of Science ®Google Scholar
• Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N. A multicenter randomized control clinical trial of Sho-saiko-to in chronic active hepatitis. Gastroenterol Jpn 1989;24:715–19.
   PubMedGoogle Scholar
• Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995;76:743–9.
   PubMed Web of Science ®Google Scholar
• Tarao K, Sakamoto Y, Ueno M, Miyakawa K, Ohkawa S. Juzentaihoto (TJ48) may be an important and effective anti-inflammatory agent for intractable cases of patients with HCV-associated chronic liver diseases. Kampo Med 2010;61:1–8.
   Google Scholar